Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis (Nasdaq: NUWE) entered a definitive securities purchase agreement with institutional investors for a registered direct offering of 1,310,890 common shares at $2.59 per share, for approximately $3.4 million in gross proceeds, priced at-the-market under Nasdaq rules.
According to Nuwellis, it also received about $3.1 million in gross proceeds from the exercise of warrants issued in its June 2026 public offering. In a concurrent private placement, investors will receive five-year warrants to purchase up to 1,310,890 additional shares at $2.59 per share. Closing is expected on or about August 3, 2026, subject to customary conditions, with Ladenburg Thalmann acting as exclusive placement agent.
Nuwellis (Nasdaq: NUWE) reported that a single-center retrospective study on its Aquadex ultrafiltration therapy in critically ill pediatric patients has been accepted for publication in Frontiers in Pediatrics. The study evaluated epoprostenol, a short-acting agent that inhibits platelet clumping, as the sole anticoagulant during Aquadex therapy.
The review of 46 children (52 treatment courses) at UPMC Children's Hospital of Pittsburgh (September 2022–September 2025) found that circuit performance was maintained, vasoactive support did not increase, platelet counts were stable or modestly higher, and no bleeding events were attributed to epoprostenol. The authors describe the work as a feasibility report rather than proof of superiority. Nuwellis said it only provided modest funding for open-access publication, with no support for conducting the research.
Nuwellis (Nasdaq: NUWE) announced its entry into Wisconsin’s pediatric critical care market through the first installations of its Aquadex SmartFlow® systems at a leading pediatric academic medical center. The collaboration aims to build clinical pathways and integrate Aquadex therapy into the hospital’s pediatric program.
The company continues to focus on pediatric and critical care expansion, targeting fluid-overloaded patients unresponsive to diuretics and weighing 20 kilograms or more. Nuwellis recently completed a pre-submission meeting with the FDA on expanding the Aquadex label to patients 5 kilograms and above and anticipates a 510(k) submission by the end of 2026.
Nuwellis (Nasdaq: NUWE) released unaudited preliminary results for the quarter ended June 30, 2026, expecting 14% year-over-year revenue growth for the second quarter and 20% growth for the first six months of 2026. Management attributes this performance to continued commercial momentum and increasing adoption of the Aquadex Ultrafiltration platform.
According to Nuwellis, final second-quarter and first-half 2026 financial results will be reported on August 13, 2026, before the U.S. market open, followed by a conference call and webcast at 9:00 a.m. Eastern time.
Nuwellis (Nasdaq: NUWE) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,678,592 for the company’s Dual Lumen Catheter, a peripheral dual-lumen catheter intended for extracorporeal therapies such as ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT). The patent was issued on July 14, 2026.
According to Nuwellis, the design uses a reinforcing stainless-steel coil to help prevent catheter collapse under negative pressure from blood pumps while allowing clinicians to trim the catheter to a patient-specific length without compromising structural integrity. The company states that this may improve blood flow, support longer filter life, and provide greater flexibility across adult and pediatric patient populations, further expanding its intellectual property portfolio in cardiorenal fluid management.
Nuwellis (Nasdaq: NUWE) will showcase its Aquadex SmartFlow therapy at the KidneyBee Summit 2026, held July 14-16, 2026 at Children's Hospital Colorado in Aurora. The company plans to engage pediatric nephrology and critical care clinicians on precise fluid management and ultrafiltration in children with acute kidney injury, cardiorenal conditions, and fluid overload.
Nuwellis (Nasdaq: NUWE) marks five years of supporting the Pediatric Cardiac Critical Care Consortium (PC4) annual conference, which focuses on care for children with critical and congenital cardiovascular disease.
The company backs clinician education on fluid management and use of its Aquadex SmartFlow ultrafiltration system in high-acuity pediatric and cardiac ICUs.
Nuwellis (Nasdaq: NUWE) announced installation of three Aquadex SmartFlow systems at a leading Michigan pediatric hospital, marking its first pediatric program in the state. The placement expands its pediatric critical care presence and supports development of clinical protocols and workflows for fluid management in children.
The Aquadex SmartFlow system provides ultrafiltration therapy for adult and pediatric patients ≥20 kg with fluid overload unresponsive to diuretics. Nuwellis also recently held an FDA pre-submission meeting on a proposed label expansion to include pediatric patients ≥5 kg.
Nuwellis (Nasdaq: NUWE)/b) shared a CEO transition and strategic update. Effective June 30, 2026, Mike McCormick becomes CEO while John Erb remains Chairman. In Q1 2026, revenue grew and gross margin reached 70.1%, a 14-point improvement.
About 75% of revenue comes from pediatric and critical care. Priorities include expanding Aquadex pediatric indications down to 5 kg, integrating the acquired Rendiatech kidney monitoring technology, strengthening capital, reducing cash burn, and targeting consistent double-digit revenue growth and continued margin expansion.
Nuwellis (Nasdaq: NUWE) supported the 4th University of Minnesota Critical Care Cardiology Education Summit by providing hands-on training with its Aquadex SmartFlow ultrafiltration system.
More than 280 physicians, including fellows and intensivists, received practical Aquadex training focused on fluid management in critically ill cardiac patients.